SEC 13F Intelligence

Managers / Q4 2020 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$157M
Q4 2020
Positions
117
Filings on Record
30
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Highvista Strategies LLC reported $157M in U.S.-listed holdings across 117 positions for Q4 2020.

The portfolio is heavily concentrated: DELL alone accounts for 31.9% of reported value.

Compared with Q3 2020, the fund opened 34 new positions and exited 30.

Portfolio Metrics

Turnover
+20.3%
vs prior filed quarter
Top-10 Concentration
+59.2%
share of reported value
Largest Position
+31.9%
Dell Technologies
New / Exited
34 / 30
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 73.2%Other: 12.8%ADR: 11.0%ETP: 3.0%Right: 0.1%Other: 0.1%
  • Common Stock · 73.2% · $115M
  • Other · 12.8% · $20M
  • ADR · 11.0% · $17M
  • ETP · 3.0% · $5M
  • Right · 0.1% · $124,000
  • Other · 0.1% · $82,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IPHIINPHI CORPNEW+21.5K21.5K+$3M$3M
XLNXEURXILINX INCNEW+24.2K24.2K+$3M$3M
BIDUNBAIDU INCNEW+15.0K15.0K+$3M$3M
SOGOGBPSOGOU INCNEW+360.0K360.0K+$3M$3M
DOUYU INTL HLDGS LTDNEW+249.6K249.6K+$3M$3M
NKTXNKARTA INCNEW+24.0K24.0K+$1M$1M
PMVPPMV PHARMACEUTICALS INCNEW+22.7K22.7K+$1M$1M
ATHIRA PHARMA INCNEW+32.1K32.1K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C31.86%$50M680.6K
2WILLIS TOWERS WATSON PLC LTDSHS5.52%$9M41.1K
3BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS4.65%$7M31.3K
4TIFEURTIFFANY & CO NEWhistory →COM4.29%$7M51.1K
5ISHARES TRMSCI INDIA ETF · MSCI INDIA SM CP2.57%$4M97.7K
6MXIMMAXIM INTEGRATED PRODS INChistory →COM2.41%$4M42.6K
7IPHIINPHI CORPhistory →COM2.21%$3M21.5K
8XLNXEURXILINX INChistory →COM2.19%$3M24.2K
9ACIAACACIA COMMUNICATIONS INChistory →COM2.07%$3M44.4K
10BIDUNBAIDU INChistory →SPON ADR REP A2.07%$3M15.0K
11FITEURFITBIT INChistory →CL A1.96%$3M451.0K
12SOGOGBPSOGOU INChistory →ADR REPSTG A1.87%$3M360.0K
13DOUYU INTL HLDGS LTDSPONSORED ADS1.76%$3M249.6K
14GNWGENWORTH FINL INChistory →COM CL A1.40%$2M578.0K
15GRUBHUB INCCOM1.32%$2M27.9K
16NKTXNKARTA INCCOM0.94%$1M24.0K
17TGTXTG THERAPEUTICS INCCOM0.90%$1M27.2K
18PMVPPMV PHARMACEUTICALS INCCOM0.89%$1M22.7K
19SUTRO BIOPHARMA INCCOM0.87%$1M63.1K
20RCKTROCKET PHARMACEUTICALS INCCOM0.86%$1M24.6K
21ATHIRA PHARMA INCCOM0.70%$1M32.1K
22STOKSTOKE THERAPEUTICS INCCOM0.70%$1M17.7K
23KYMRKYMERA THERAPEUTICS INCCOM0.68%$1M17.1K
241K0IGM BIOSCIENCES INCCOM0.67%$1M12.0K
25TREURTRILLIUM THERAPEUTICS INCCOM NEW0.64%$1M68.2K
26CYTKCYTOKINETICS INCCOM NEW0.63%$987,00047.5K
27NEOLEUKIN THERAPEUTICS INCCOM0.63%$983,00069.7K
28SRPTSAREPTA THERAPEUTICS INCCOM0.62%$966,0005.7K
29TSMTAIWAN SEMICONDUCTOR MFG LTDSPONSORED ADS0.61%$955,0008.8K
30IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.61%$948,00020.4K
31ARNAEURARENA PHARMACEUTICALS INCCOM NEW0.59%$931,00012.1K
32CNSTCONSTELLATION PHARMCETICLS ICOM0.59%$918,00031.9K
33AM6AMICUS THERAPEUTICS INCCOM0.59%$918,00039.8K
34SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.57%$900,00012.4K
35AXSMAXSOME THERAPEUTICS INCCOM0.57%$897,00011.0K
36CCXIEURCHEMOCENTRYX INCCOM0.57%$896,00014.5K
37TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.56%$873,00049.9K
38ADAPYADAPTIMMUNE THERAPEUTICS PLCSPONDS ADR0.55%$859,000159.4K
39SG7SAGE THERAPEUTICS INCCOM0.54%$838,0009.7K
40IMVTIMMUNOVANT INCCOM0.53%$827,00017.9K
41ARGXARGENX SESPONSORED ADR0.52%$818,0002.8K
42ALTALTIMMUNE INCCOM NEW0.52%$816,00072.4K
43OPHTEURIVERIC BIO INCCOM0.52%$809,000117.1K
44KURAKURA ONCOLOGY INCCOM0.52%$807,00024.7K
45MGNXMACROGENICS INCCOM0.51%$791,00034.6K
46ASCENDIS PHARMA A/SSPONSORED ADR0.50%$789,0004.7K
47MRTXEURMIRATI THERAPEUTICS INCCOM0.50%$783,0003.6K
48ACADACADIA PHARMACEUTICALS INCCOM0.49%$767,00014.3K
49GBTUSDGLOBAL BLOOD THERAPEUTICS INCOM0.48%$753,00017.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.